News Release

Maruho Establishes New Research Base -Installation of Satellite Lab at Shonan iPark-

Osaka (Japan), November 15, 2019 - Maruho Co., Ltd ("Maruho", Head Office: Osaka, Japan, President and CEO: Koichi Takagi) announces that in order to accelerate innovation in pharmaceutical research and development in dermatology, as of November 15, 2019 it has newly established a satellite laboratory, Maruho Shonan Innovation Lab (MSiL) at Shonan Health Innovation Park ("Shonan iPark", Fujisawa City, Kanagawa Prefecture, General Manager: Dr. Toshio Fujimoto).

With the long-term vision "Excellence in Dermatology", Maruho aims to expand its business from a focus on therapeutic drugs to cover the entire care cycle (prevention, examination/diagnosis, treatment, and aftercare) to meet a wider range of patient needs related to skin diseases. Previously, Maruho has mainly worked on research and development of pharmaceuticals utilizing open innovation in Kyoto Research Park (Kyoto City, Kyoto Prefecture).

In addition to pharmaceutical companies and drug discovery ventures, Shonan iPark is home to drug discovery support services, medical devices, and AI / IoT companies, creating a life science ecosystem that is open to the world. Through this new satellite lab, MSiL, Maruho will develop its network and gain further opportunities to collaborate with various partners.

Through these collaborations, Maruho aims to further contribute to patients suffering from skin diseases by promoting the creation and introduction of new solutions related to the care cycle, beginning with pharmaceutical research and development.

About Maruho Shonan Innovation Lab (MSiL)
Location: 26-1 Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
Established: November 15, 2019

About Maruho
Maruho Co., Ltd. has its headquarters in Osaka and leads Japan in research and development, manufacturing and commercialization of dermatological products. Founded in 1915, Maruho has 1,512 employees (as of the end of September 2018), and net sales were approximately 78.57 billion yen in its fiscal year ending September 30, 2018. Pursuing its long-term corporate vision of "Excellence in Dermatology," Maruho is striving to improve the health and quality of life of people all over the world.
For more information, please visit

About Shonan Health Innovation Park (Shonan iPark)
Takeda Pharmaceutical Co., Ltd. launched Shonan iPark by transforming its Shonan research site to enhance scientific innovation. Shonan iPark is built on pharmaceutical know-how, with experts from the industry including, venture startups, government, and academia coming together to incubate and accelerate research, with the aim of translating cutting-edge science into impactful health solutions.
For more information, please visit

Back to Top